IMP 08P2002F0

Phase 2Small molecule

UUnither Pharmaceuticals, France

IMP 08P2002F0 is one of 4 small molecule programs targeting Mydriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MydriasisNot yet recruiting

MydriasisPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Mydriasis

#DrugCompanyPhaseTrials

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—3

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

—4

IMP 08P2002F0

UUnither Pharmaceuticals, France

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution

Not yet recruiting·UUnither Pharmaceuticals, France·Phase 1/2·NCT07075224·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IMP 08P2002F0. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMP 08P2002F0 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMP 08P2002F0. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unither Pharmaceuticals, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUnither Pharmaceuticals, France

IMP 08P2002F0

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News